Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @CDRLifeSciences
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CDRLifeSciences
-
CDR Life Sciences proslijedio/la je Tweet
(Enterome collaborates with BIOASTER Institute) -
@BIOASTER@EnteromeSA#microbiome - https://www.bioaster.org/?p=2490 pic.twitter.com/AltvO53DM7
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
Our COO, Simon Baeriswyl, is talking to @ScripLucie at
#LSXWorld Congress about our Pharma partnerships, in particular our licensing and co-development deal with Takeda#microbiomepic.twitter.com/sHkh7QFdQ1
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
@Enesi_Pharma are attending the BIO CEO & Investor Conference from 10-11 February 2020 in New York.@DavidHipkiss will be presenting our#ImplaVax needle-free solid dose#vaccine technology on Monday 10th February@1.45pm in the Wilder Room.#VaccinesWorkpic.twitter.com/f2pHtKuhEC
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
@Enesi_Pharma is excited to be nominated for a ViE Award in the Best New Vaccine Technology/Platform (category #7). Please vote for us here to recognise the potential of our ImplaVax® vaccination technology platform https://www.terrapinn.com/conference/world-vaccine-congress-washington/ViE-Awards-Voting.stm …#VaccinesWorkpic.twitter.com/c66K7e727i
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
New Funds Extend Chi-Med’s Runway But HK Listing Still Planned http://bit.ly/37IXLsA
#PharmaScripHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
The collaboration “shows early but enormous potential for the treatment of
#cancers.”@forbes@ForbesScience@cardiffuni@ErvaxxLtd#cancer#cancerresearch#cancertreatment#tcell#immunotherapies#healthcare#tcellcancertherapies#personalizedmedicinehttps://bit.ly/2t4RubzHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
We start 2020 with the first novel drug designed by
#AI entering human clinical trials. By the end of this new decade, we expect all drugs will be developed using AI. Read@madhumita29’s piece about this critical milestonehttps://twitter.com/FT/status/1222736229617360897 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
Cardiff University and Ervaxx turn to the dark side to fight cancer
@cardiffuni is looking to@ErvaxxLtd and their Dark Antigens to build on research which could lead to a universal#cancer treatment.#longevity#DarkAntigens https://bit.ly/30WAAZd pic.twitter.com/LRV4vmZbYG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
"Treatment with [TYK2/JAK1 inhibitor] PF-06700841 rapidly improves disease activity in patients with chronic plaque psoriasis by inhibiting pro-inflammatory cytokines that require TYK2 and JAK1 for signal transduction" https://www.ncbi.nlm.nih.gov/pubmed/31972249
$SAR.L#TYK2Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Acacia Pharma
#ACPH$ACPH has been awarded BEL Small Company of the Year 2019 by@euronext_be at its New Year Ceremony last night https://bit.ly/30TTj7F pic.twitter.com/nrc5bzX62G
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
Thrilled today to announce our collaboration with
@cardiffuni to develop novel#Tcell and#TCR immunotheraies targeting#DarkAntigens. We will also build on exciting new research in@NatImmunol identifying#MR1 as a target for novel#immunotherapy. https://bit.ly/2NRXifB pic.twitter.com/FcOr48OaMr
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
Congratulations to Jackie Grant, Principal in our Boston, MA office, who has been elected to the Board of Directors of
@MALifeSciences Centerpic.twitter.com/O9vSp8zv7z
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Oculis announces upcoming presentation of Phase 2 data of OCS-01, its investigational topical back-of-the-eye treatment, in patients with
#Diabetic#Macular#Edema (#DME) on 8 February at Angiogenesis, Exudation, and Degeneration 2020 https://bit.ly/37jkpYm pic.twitter.com/vJtvYOrtz4
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
Antabio’s CF program funded by CARB-X highlighted in Forbes
#cysticfibrosis@CARB_X@antabiohttps://lnkd.in/gZCJvcyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
Early stop of SANET-p Phase III after +ve interim analysis. Likely
#surufatinib China NDA filing (2nd indication) in 2020 & potentially unique position as effective therapy across the NET (#neuroendcrinetumours) spectrum. Read more on@HChiMed$HCM at:https://www.trinitydelta.org/companies/chi-med/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
Key message from Albert Baehny, Chairman and CEO ad interim, on our
#LonzaFullYear2019 results:pic.twitter.com/FETOLpT9kL
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
Immuno-oncology (including Sareum's SDC-1802): All you wanted to know but were too afraid to ask http://tinyurl.com/yyemzs6g via
@proactive_UK$SAR.L#AIM#biotech#tyk2Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
Drug would be Chi-Med's first fully independent launch in
#China#pharma More Surufatinib Cheer For Chi-Med As Second NET Trial Stopped Earlyhttps://scrip.pharmaintelligence.informa.com/articles/2020/01/20/more-surufatinib-cheer-for-chimed-as-second-net-trial-stopped-early …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CDR Life Sciences proslijedio/la je Tweet
More Surufatinib Cheer For Chi-Med As Second NET Trial Stopped Early http://bit.ly/38iQvUe
#PharmaScripHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.